Farmacotherapy

Rol actual de los nuevos antiplaquetarios en el síndrome coronario agudo

solaci
solaci
520
0

Ramon-Corbalan

Ramón Corbalan
2011-08-03

Previous article
Evaluación de enfermedad coronaria con SPECT y PET
Next article
Therapeutic strategies for the control of dyslipemia
solaci
solaci

More articles by this author

Antiplatelet therapy advance in ACS and PCI

solaci - 0
Jorge Belardi 2011-08-05

Interruption of antiplatelet therapy for non-cardiac surgery

solaci - 0
Ajay Kirtane 2011-08-03

Protección gástrica en pacientes sometidos a angioplastia coronaria

solaci - 0
Gastón Dussaillant 2011-08-03

Therapeutic strategies for the control of dyslipemia

solaci - 0
Ada Cuevas 2011-08-03

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Farmacotherapy

Antiplatelet therapy advance in ACS and PCI

Jorge Belardi 2011-08-05
solaci -
SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Dr. Andrés Rodríguez - 0
Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

Dr. Andrés Rodríguez - 0
According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

Dr. Andrés Rodríguez - 0
The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...